Yeah I agree. The company's future is probably ok, but you need some spectacular things to happen when you buy the stock paying a forward FY15 PE of 35. It makes XRO look dirt cheap.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025